CLINICAL_TRIALS
trial_result
· 2016-08-02
Clinical Trial Update: CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris [Phase 2]
Summary
A Phase 2 clinical trial evaluating CTX-4430 for moderate to severe facial acne vulgaris has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Celtaxsys, Inc. | Conditions: Acne Vulgaris | Phase 2 | Status: COMPLETED